EGFR and non-small cell lung carcinoma: Targeted therapies, represented by epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), have greatly improved the quality of life and prognosis of patients with non-small cell lung cancer (NSCLC) [2].